133077-43-7

Basic information

• Product Name: C₉H₈ClFO₂
• Synonyms: C₉H₈ClFO₂
• CAS NO: 133077-43-7
• Molecular Weight: 202.613
• Mol File: 133077-43-7.mol

Chemical Properties

• CAS DataBase Reference: C₉H₈ClFO₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₉H₈ClFO₂(133077-43-7)
• EPA Substance Registry System: C₉H₈ClFO₂(133077-43-7)

Safety Data

• Hazardous Substances Data: 133077-43-7(Hazardous Substances Data)

Upstream product

• 133077-42-6 3-(3-fluorophenoxy)propanoic acid 
• 844648-05-1 3-(3-fluorophenoxy)propanenitrile 
• 372-20-3 3-fluorophenol 

Downstream Products

• 188826-32-6 5-fluoro-2,3-dihydro-4H-chromen-4-one 
• 1630952-72-5 8-(5-fluorochroman-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
• 66892-34-0 6-fluoro-4-chromanone 

Relevant articles and documents

Facile access to chiral 4-substituted chromanes through Rh-catalyzed asymmetric hydrogenation

Rh/ZhaoPhos-catalyzed asymmetric hydrogenation of a series of (E)-2-(chroman-4-ylidene)acetates was successfully developed to prepare various chiral 4-substituted chromanes with high yields and excellent enantioselectivities (up to 99percent yield, 98percent ee). Moreover, the gram-scale hydrogenation could be performed well in the presence of 0.02 molpercent catalyst loading (TON = 5000), the hydrogenation product was easily converted to access other important compounds, which demonstrated the synthetic utility of this asymmetric catalytic methodology.

Synthesis, enantiomeric separation and docking studies of spiropiperidine analogues as ligands of the nociceptin/orphanin FQ receptor

A series of triazospirodecanone derivatives were synthesized as potential NOP ligands. 8-(Chroman-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (4) and its 5-fluoro analogue (18) proved to be active as agonists with EC50 values in the submicromolar range. Single enantiomers of compound 4 were separated and tested as NOP agonists; the eutomer R-(+)-4 showed a pEC 50 of 7.34. Finally docking studies were performed on the NOP receptor to identify the most significant stereospecific interactions.